Seroquel Articles
AstraZeneca sues US FDA over Seroquel decision
13 March 2012
AstraZeneca Seroquel petitions denied by US FDA
9 March 2012
AstraZeneca wins UK approval for Seroquel XL in major depression
29 September 2010
European approval for Merck & Co/Cardiome’s IV Brinavess; added use for AstraZeneca’s Seroquel recommended
2 September 2010
Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis
5 August 2010
New study finds off-label use of atypical antipsychotics increases risk of diabetes among the elderly
14 May 2010
US jury finds in favor of AstraZeneca in Seroquel product liability case; Clinigen takes over Foscavir
19 March 2010
AstraZeneca’s CEO defends company’s stance in Bloomberg interview
15 February 2010
Safety and clinical benefits of AstraZeneca’s Seroquel XR need to be demonstrated for its approval as an MDD monotherapy, says DR
28 January 2010
US FDA approves AstraZeneca’s Seroquel XR for add-on treatment of MMD and standard drug for pediatric use
4 December 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
AstraZeneca beats consensus forecasts with 3rd quarter 2009 profits up 22% raises forecasts
29 October 2009
Atypical antipsychotics cause significant weight gain in children and young adults, JAMA study reports
28 October 2009
AstraZeneca’s Seroquel gets EU approval for bipolar recurrence
30 September 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Seroquel shows strong bipolar results at APA
2 June 2009
Stock Commentary - Europe - week to April 13, 2009
16 April 2009
Seroquel unsafe for new indications; panel
9 April 2009
FDA to discuss Seroquel sNDA in two months
31 March 2009
AstraZeneca challenges medical experts in Seroquel case
16 March 2009
Stock Commentary - Europe - week to mar 2, 2009
9 March 2009
AZ gets FDA complete response on Seroquel in GAD
9 March 2009
AZ e-mail reveals "buried"Seroquel data
9 March 2009
AZ awaits news of new indications for Seroquel
2 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
AstraZeneca's Seroquel XR launched in USA
2 March 2009
UPDATE: Dutch NGO's CT claims rebutted by GSK and AZ
16 February 2009
FDA asks for more info on Seroquel in MDD
12 January 2009
Tentative FDA OK for Teva's generic Seroquel
12 January 2009
FDA warns AZ of off-label promotion case
15 December 2008
Biovail files ANDA for quetiapine
8 December 2008
AstraZeneca files Seroquel for GAD in Europe
27 October 2008
FDA nod for Seroquel XR in bipolar disorder
20 October 2008
AZ reports good results for Seroquel XR in GAD
8 September 2008
Stock Commentary - Europe - week to July7, 2008
14 July 2008
AZ: new data from Seroquel trials
14 July 2008
US court rules for AstraZeneca in Seroquel case
7 July 2008
AstraZeneca submits EU MAA for Seroquel XR in MDD
16 June 2008
AZ submits sNDA for Seroquel to treat GAD
19 May 2008
Seroquel XR fares well in MDD and GAD
19 May 2008
J&J drug: longer time to relapse than quetiapine
12 May 2008
Promotional spending on atypical antipsychotice analyzed
17 March 2008
Seroquel XR filed with FDA for MDD
10 March 2008
AstraZeneca files Seroquel for MDD with MHRA
25 February 2008
AstraZeneca files for new Seroquel indication in EU
18 February 2008
AstraZeneca's net profit falls 12% on restructing charges from MedImmune buy, lower Nexium sales
11 February 2008
AstraZeneca's Seroquel cuts rate of mood events
4 February 2008
AZ files Seroquel XR for biopolar mania and depression
14 January 2008
Seroquel impresses in MDD and GAD studies
10 December 2007
FDA clears Seroquel XR as maintenance therapy
26 November 2007
Addendum: Janssen/J&J's Invega
22 October 2007
Review of the annual meeting of the ECNP
22 October 2007
Invega signficantly cuts schizophrenia vs Seroquel
22 October 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Janssen and AstraZeneca drugs now lead antipsychotics
24 September 2007
Dutch approval for AstraZeneca's once-daily Seroquel XR
3 September 2007
Seroquel as effective as olanzapine in mania
3 September 2007
Attempt at drug funds transparency criticized
20 August 2007
FDA approves XR Seroquel for schizophrenia
28 May 2007
Waxman investigates marketing practices
12 March 2007
AstraZeneca's R&D pipeline update reveals 120 NCEs and 25 LCM strategies in progress
12 February 2007
Seroquel upgraded to first-line therapy in CANMAT guidelines
11 December 2006
Lilly maintains cost-effectiveness of Zyprexa
11 December 2006
Stock Commentary - Europe - week to Nov 27
4 December 2006
New hope for sufferers of manic-depression from unlikely sources
4 December 2006
AstraZeneca's Seroquel shows potential in BOLDER II trial
27 November 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
